| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 2e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.25 | 9e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.23 | 0.0002 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.17 | 0.0003 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |